Daniel M. Kim

Daniel M. Kim

Auto-generated profile, based on publicly available information

Daniel M. Kim

Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2024 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
HCHewitt Chang
Hewitt Chang
JMJaqueline Marquez
Jaqueline Marquez
BCBrandon K. Chen
Brandon K. Chen
DKDaniel M. Kim
Daniel M. Kim
MCMichael L. Cheng
Michael L. Cheng
LFLawrence Fong
Lawrence Fong
Denosumab is a fully human mAb that binds receptor activator of NFκB ligand (RANKL). It is routinely administered to patients with cancer to reduce the incidence of new bone metastasis. RANK–RANKL interactions regulate bone turnover by controlling osteoclast recruitment, development, and activity. However, these interactions also can regulate immune cells including dendritic cells and medullary thymic epithelial cells. Inhibition of the latter results in reduced thymic negative selection of T cells and could enhance the generation of tumor-specific T cells. We examined whether administering denosumab could modify modulate circulating immune cells in patients with cancer. Blood was collected from 23 patients with prostate cancer and 3 patients with renal cell carcinoma, all of whom had advanced disease and were receiving denosumab, prior to and during denosumab treatment. Using high-dimensional mass cytometry, we found that denosumab treatment by itself induced modest effects on circulating immune cell frequency and activation. We also found minimal changes in the circulating T-cell repertoire and the frequency of new thymic emigrants with denosumab treatment. However, when we stratified patients by whether they were receiving chemotherapy and/or steroids, patients receiving these concomitant treatments showed significantly greater immune modulation, including an increase in the frequency of natural killer cells early and classical monocytes later. We also saw broad induction of CTLA-4 and TIM3 expression in circulating lymphocytes and some monocyte populations. These findings suggest that denosumab treatment by itself has modest immunomodulatory effects, but when combined with conventional cancer treatments, can lead to the induction of immunologic checkpoints. See related Spotlight by Nasrollahi and Davar, p. 383.

2 April 2024
Verified
Other
Open access
HCHewitt Chang
Hewitt Chang
JMJaqueline Marquez
Jaqueline Marquez
BCBrandon K. Chen
Brandon K. Chen
DKDaniel M. Kim
Daniel M. Kim
MCMichael L. Cheng
Michael L. Cheng
LFLawrence Fong
Lawrence Fong
Denosumab is a fully human mAb that binds receptor activator of NFκB ligand (RANKL). It is routinely administered to patients with cancer to reduce the incidence of new bone metastasis. RANK–RANKL interactions regulate bone turnover by controlling osteoclast recruitment, development, and activity. However, these interactions also can regulate immune cells including dendritic cells and medullary thymic epithelial cells. Inhibition of the latter results in reduced thymic negative selection of T cells and could enhance the generation of tumor-specific T cells. We examined whether administering denosumab could modify modulate circulating immune cells in patients with cancer. Blood was collected from 23 patients with prostate cancer and 3 patients with renal cell carcinoma, all of whom had advanced disease and were receiving denosumab, prior to and during denosumab treatment. Using high-dimensional mass cytometry, we found that denosumab treatment by itself induced modest effects on circulating immune cell frequency and activation. We also found minimal changes in the circulating T-cell repertoire and the frequency of new thymic emigrants with denosumab treatment. However, when we stratified patients by whether they were receiving chemotherapy and/or steroids, patients receiving these concomitant treatments showed significantly greater immune modulation, including an increase in the frequency of natural killer cells early and classical monocytes later. We also saw broad induction of CTLA-4 and TIM3 expression in circulating lymphocytes and some monocyte populations. These findings suggest that denosumab treatment by itself has modest immunomodulatory effects, but when combined with conventional cancer treatments, can lead to the induction of immunologic checkpoints.See related Spotlight by Nasrollahi and Davar, p. 383.

2 April 2024
Verified
Other
Open access
HCHewitt Chang
Hewitt Chang
JMJaqueline Marquez
Jaqueline Marquez
BCBrandon K. Chen
Brandon K. Chen
DKDaniel M. Kim
Daniel M. Kim
MCMichael L. Cheng
Michael L. Cheng
LFLawrence Fong
Lawrence Fong
Supplementary Figure 1: Manual gating strategy A representative patient sample was used to illustrate the gating strategy on Cytobank to create pre-determined landmark nodes for scaffold analysis and clustering.

2 April 2024
Verified
Other
Open access
HCHewitt Chang
Hewitt Chang
JMJaqueline Marquez
Jaqueline Marquez
BCBrandon K. Chen
Brandon K. Chen
DKDaniel M. Kim
Daniel M. Kim
MCMichael L. Cheng
Michael L. Cheng
LFLawrence Fong
Lawrence Fong
Supplementary Table 3: primer sequences

4 April 2024
Verified
Other
Open access
HCHewitt Chang
Hewitt Chang
JMJaqueline Marquez
Jaqueline Marquez
BCBrandon K. Chen
Brandon K. Chen
DKDaniel M. Kim
Daniel M. Kim
MCMichael L. Cheng
Michael L. Cheng
LFLawrence Fong
Lawrence Fong
Denosumab is a fully human mAb that binds receptor activator of NFκB ligand (RANKL). It is routinely administered to patients with cancer to reduce the incidence of new bone metastasis. RANK–RANKL interactions regulate bone turnover by controlling osteoclast recruitment, development, and activity. However, these interactions also can regulate immune cells including dendritic cells and medullary thymic epithelial cells. Inhibition of the latter results in reduced thymic negative selection of T cells and could enhance the generation of tumor-specific T cells. We examined whether administering denosumab could modify modulate circulating immune cells in patients with cancer. Blood was collected from 23 patients with prostate cancer and 3 patients with renal cell carcinoma, all of whom had advanced disease and were receiving denosumab, prior to and during denosumab treatment. Using high-dimensional mass cytometry, we found that denosumab treatment by itself induced modest effects on circulating immune cell frequency and activation. We also found minimal changes in the circulating T-cell repertoire and the frequency of new thymic emigrants with denosumab treatment. However, when we stratified patients by whether they were receiving chemotherapy and/or steroids, patients receiving these concomitant treatments showed significantly greater immune modulation, including an increase in the frequency of natural killer cells early and classical monocytes later. We also saw broad induction of CTLA-4 and TIM3 expression in circulating lymphocytes and some monocyte populations. These findings suggest that denosumab treatment by itself has modest immunomodulatory effects, but when combined with conventional cancer treatments, can lead to the induction of immunologic checkpoints.See related Spotlight by Nasrollahi and Davar, p. 383.

2 April 2024
Verified
Other
Open access
HCHewitt Chang
Hewitt Chang
JMJaqueline Marquez
Jaqueline Marquez
BCBrandon K. Chen
Brandon K. Chen
DKDaniel M. Kim
Daniel M. Kim
MCMichael L. Cheng
Michael L. Cheng
LFLawrence Fong
Lawrence Fong
Supplementary Figure 3: Expression of immune checkpoints at baseline (A) A uniform manifold approximation and projection (UMAP) plot of cells from all peripheral blood mononuclear cell (PBMC) samples analyzed with Scaffold using data from cytometry by time of flight (CyTOF). Clusters correspond to canonical immune cells and are represented by distinct colors. (B) Expression of PD-L1, TIM3, and CTLA-4 at baseline and post-treatment timepoint 2 (TP2). Raw count of metal ions detected from CyTOF were asinh-transformed, with a higher value corresponding to a higher expression of immune checkpoint.